Kinsey and White (1940) found clinical evidence of pulmonary infarction in 14 % of patients surviving episodes of cardiac failure and in 29% of those dying in heart failure but not submitted to necropsy. Where necropsy was carried out the incidence of pulmonary infarction was found to be nearly 50%. Wishart and Chapman (1948) found clinical or necropsy evidence of pulmonary embolism in only 6.5 % of patients with congestive heart failure given bishydroxycoumarin (dicoumarol) prophylactically. Subsequent trials have shown an incidence of thromboembolic complications ranging from 2% to 7% in congestive-failure patients given anticoagulants, as compared with 8 % to 33 % of controls
found clinical evidence of pulmonary infarction in 14 % of patients surviving episodes of cardiac failure and in 29% of those dying in heart failure but not submitted to necropsy. Where necropsy was carried out the incidence of pulmonary infarction was found to be nearly 50%. Wishart and Chapman (1948) found clinical or necropsy evidence of pulmonary embolism in only 6.5 % of patients with congestive heart failure given bishydroxycoumarin (dicoumarol) prophylactically. Subsequent trials have shown an incidence of thromboembolic complications ranging from 2% to 7% in congestive-failure patients given anticoagulants, as compared with 8 % to 33 % of controls (Anderson and Hull, 1950; Harvey and Finch, 1950 ; Griffith, 1952 ;  Thorsen, 1957) . As a result of such evidence, routine administration of anticoagulants to patients in congestive heart failure has been recommended (Brit. med. 7., 1963 ; Owren, 1963) .
The apparent benefits of prophylactic anticoagulant therapy have to be weighed against its difficulties and dangers. Recent advances in the general treatment of congestive failure may, by shortening the period of bed-rest required, have reduced the risk of thromboembolic complications in this condition. The following controlled trial was undertaken to reassess the risk of these complications and to define the place of anticoagulants in a modern congestive-failure regimen.
Methods
Patients with congestive cardiac failure, admitted under the care of one consultant physician to one ward of the hospital during the period April 1962 to April 1965, formed the basis of the study. Alternate patients were given prophylactic anticoagulant therapy unless there was a specific contraindication such as peptic ulcer. Patients with a contraindication were not excluded from the trial but were placed in the " control " group. Apart from the anticoagulant drug, therapy was generally similar in both " treatment " and " control " groups.
The anticoagulant used was phenindione, and therapy was begun with a single dose of 100 mg. on the first day followed by two doses of 50 mg. on the second day. (1940) . The 10% incidence of thromboembolic complications found in our control group is comparable with the 8 % incidence found by Anderson and Hull (1950) The implications of the difference in time of embolism here found must remain in some doubt, since we lack information regarding the period of domiciliary bed-rest, before admission to hospital, for the two groups. However, the two groups are so similar in all respects for which information is available that a significant difference in this regard seems unlikely. It is also the case that bed-rest at home is rarely as complete as is the rule in hospital, and that there was not one thromboembolic episode in the control group during the first six days after admission. The possibility that the early occurrence of thromboembolism in the anticoagulated group is in some way related to the anticoagulant therapy given must therefore be entertained.
There is some experimental evidence to suggest that small doses of heparin or dicoumarol may actually be thrombogenic (Merskey and Drapkin, 1965 (Weiner et ac., 1955) , perhaps with heparin for the first day or two, may offer a preferable alternative.
Summary
The incidence of pulmonary embolism in 76 patients with congestive cardiac failure given prophylactic (oral) anticoagulant therapy was 8 %. The incidence in a similar control series of 80 such patients not given anticoagulants was 10%.
Anticoagulant prophylaxis with phenindione, instituted at the time of admission, appears to afford protection against venous thromboembolic complications after the first 10 days, but this advantage is counterbalanced by an apparently increased tendency to such episodes during the first week or 10 days of administration of the drug.
The risk of thromboembolism in patients with clinically mild degrees of failure is too small to warrant routine anticoagulant drug prophylaxis.
